Compare Stocks: RLMD, AMLX, AGIO, and IOVA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$30.54 +1.7%	$34.53	$22.24 ▼ $46.00	$1.79B	0.54	1.24 million shs	1.19 million shs
AMLX Amylyx Pharmaceuticals	$20.17 -0.7%	$16.68	$7.48 ▼ $20.94	$2.26B	-0.21	1.71 million shs	1.69 million shs
IOVA Iovance Biotherapeutics	$4.32 +6.1%	$4.31	$1.76 ▼ $5.64	$1.82B	0.71	16.11 million shs	13.01 million shs
RLMD Relmada Therapeutics	$5.30 -0.2%	$6.21	$0.55 ▼ $8.00	$556.97M	0.46	1.66 million shs	1.07 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	+1.73%	-17.39%	-18.73%	+12.24%	-12.74%
AMLX Amylyx Pharmaceuticals	-0.69%	+3.49%	+10.40%	+22.76%	+161.27%
IOVA Iovance Biotherapeutics	+6.14%	-11.84%	+0.23%	+8.54%	+61.19%
RLMD Relmada Therapeutics	-0.19%	+1.92%	-15.61%	-27.89%	+797.70%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$30.54 +1.7%	$34.53	$22.24 ▼ $46.00	$1.79B	0.54	1.24 million shs	1.19 million shs
AMLX Amylyx Pharmaceuticals	$20.17 -0.7%	$16.68	$7.48 ▼ $20.94	$2.26B	-0.21	1.71 million shs	1.69 million shs
IOVA Iovance Biotherapeutics	$4.32 +6.1%	$4.31	$1.76 ▼ $5.64	$1.82B	0.71	16.11 million shs	13.01 million shs
RLMD Relmada Therapeutics	$5.30 -0.2%	$6.21	$0.55 ▼ $8.00	$556.97M	0.46	1.66 million shs	1.07 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	+1.73%	-17.39%	-18.73%	+12.24%	-12.74%
AMLX Amylyx Pharmaceuticals	-0.69%	+3.49%	+10.40%	+22.76%	+161.27%
IOVA Iovance Biotherapeutics	+6.14%	-11.84%	+0.23%	+8.54%	+61.19%
RLMD Relmada Therapeutics	-0.19%	+1.92%	-15.61%	-27.89%	+797.70%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.40	Hold	$40.88	33.84% Upside
AMLX Amylyx Pharmaceuticals	2.90	Moderate Buy	$25.38	25.81% Upside
IOVA Iovance Biotherapeutics	2.30	Hold	$8.43	95.11% Upside
RLMD Relmada Therapeutics	2.75	Moderate Buy	$12.00	126.42% Upside

Current Analyst Ratings Breakdown

Latest RLMD, AMLX, AGIO, and IOVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	AMLX Amylyx Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $26.00
7/31/2026	AGIO Agios Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$46.00 ➝ $52.00
7/31/2026	AGIO Agios Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$41.00 ➝ $39.00
7/30/2026	AGIO Agios Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$52.00 ➝ $55.00
7/21/2026	AGIO Agios Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$54.00 ➝ $52.00
7/20/2026	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$21.00 ➝ $24.00
7/7/2026	AGIO Agios Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$28.00 ➝ $32.00
7/7/2026	AGIO Agios Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$36.00 ➝ $41.00
7/7/2026	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $46.00
7/2/2026	IOVA Iovance Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/25/2026	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$30.00 ➝ $40.00

(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$98.34M	18.47	N/A	N/A	$20.46 per share	1.49
AMLX Amylyx Pharmaceuticals	$87.37M	25.67	N/A	N/A	$2.78 per share	7.26
IOVA Iovance Biotherapeutics	$263.50M	7.32	N/A	N/A	$1.76 per share	2.45
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$1.18 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	-$412.78M	-$7.01	N/A	N/A	N/A	-418.24%	-35.67%	-33.06%	N/A
AMLX Amylyx Pharmaceuticals	-$144.74M	-$1.50	N/A	N/A	N/A	N/A	-55.69%	-50.73%	8/6/2026 (Estimated)
IOVA Iovance Biotherapeutics	-$390.98M	-$0.95	N/A	N/A	N/A	-123.92%	-50.17%	-38.77%	8/6/2026 (Estimated)
RLMD Relmada Therapeutics	-$57.38M	-$1.09	N/A	N/A	N/A	N/A	-71.22%	-64.46%	8/6/2026 (Estimated)

Latest RLMD, AMLX, AGIO, and IOVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	AMLX Amylyx Pharmaceuticals	-$0.3609	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	IOVA Iovance Biotherapeutics	-$0.1335	N/A	N/A	N/A	$87.67 million	N/A
8/6/2026	Q2 2026	RLMD Relmada Therapeutics	-$0.21	N/A	N/A	N/A	N/A	N/A
7/30/2026	Q2 2026	AGIO Agios Pharmaceuticals	-$1.65	-$1.69	-$0.04	-$1.69	$26.40 million	$44.75 million
5/12/2026	Q1 2026	RLMD Relmada Therapeutics	-$0.18	-$0.22	-$0.04	-$0.22	N/A	N/A
5/7/2026	Q1 2026	AMLX Amylyx Pharmaceuticals	-$0.34	-$0.37	-$0.03	-$0.37	N/A	N/A
5/7/2026	Q1 2026	IOVA Iovance Biotherapeutics	-$0.19	-$0.19	N/A	-$0.19	$77.84 million	$71.43 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	10.22	9.79
AMLX Amylyx Pharmaceuticals	N/A	17.85	17.85
IOVA Iovance Biotherapeutics	N/A	3.60	3.15
RLMD Relmada Therapeutics	N/A	18.25	18.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
AMLX Amylyx Pharmaceuticals	95.84%
IOVA Iovance Biotherapeutics	77.03%
RLMD Relmada Therapeutics	45.24%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	5.40%
AMLX Amylyx Pharmaceuticals	10.90%
IOVA Iovance Biotherapeutics	7.80%
RLMD Relmada Therapeutics	14.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	59.47 million	56.48 million	Optionable
AMLX Amylyx Pharmaceuticals	200	111.19 million	99.07 million	Optionable
IOVA Iovance Biotherapeutics	500	446.50 million	411.68 million	Optionable
RLMD Relmada Therapeutics	10	104.89 million	89.68 million	Optionable

RLMD, AMLX, AGIO, and IOVA Headlines

Recent News About These Companies

Novo Nordisk A/S (NYSE:NVO) and Relmada Therapeutics (NASDAQ:RLMD) Head-To-Head Contrast

1 hour ago | americanbankingnews.com

Janus Henderson Group PLC Increases Position in Relmada Therapeutics, Inc. $RLMD

August 2 at 5:28 AM | marketbeat.com

597,409 Shares in Relmada Therapeutics, Inc. $RLMD Bought by Stempoint Capital LP

July 30, 2026 | marketbeat.com

Relmada Therapeutics (RLMD) to Release Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

ADAR1 Capital Management LLC Grows Stock Position in Relmada Therapeutics, Inc. $RLMD

July 29, 2026 | marketbeat.com

210,525 Shares in Relmada Therapeutics, Inc. $RLMD Bought by Ally Bridge Group NY LLC

July 29, 2026 | marketbeat.com

Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer

July 28, 2026 | globenewswire.com

Relmada Therapeutics Appoints Bipin Dalmia as Chief Business Officer to Advance NDV-01 and Corporate Growth

July 28, 2026 | quiverquant.comQ

Eversept Partners LP Buys New Shares in Relmada Therapeutics, Inc. $RLMD

July 28, 2026 | marketbeat.com

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

July 28, 2026 | americanbankingnews.com

Relmada Therapeutics, Inc. $RLMD Stock Holdings Increased by Orbimed Advisors LLC

July 27, 2026 | marketbeat.com

Commodore Capital LP Acquires New Position in Relmada Therapeutics, Inc. $RLMD

July 27, 2026 | marketbeat.com

Spruce Street Capital LP Buys 2,175,933 Shares of Relmada Therapeutics, Inc. $RLMD

July 25, 2026 | marketbeat.com

Knott David M Jr Makes New $3.06 Million Investment in Relmada Therapeutics, Inc. $RLMD

July 24, 2026 | marketbeat.com

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Given Consensus Recommendation of "Moderate Buy" by Analysts

July 23, 2026 | marketbeat.com

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Significant Growth in Short Interest

July 17, 2026 | marketbeat.com

Relmada Therapeutics (NASDAQ:RLMD) Stock Price Down 10.5% - Here's What Happened

July 16, 2026 | marketbeat.com

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

July 16, 2026 | globenewswire.com

Relmada Therapeutics Joins Russell 2000 Index And Russell 3000 Index

June 29, 2026 | benzinga.com

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

June 29, 2026 | globenewswire.com

Relmada: NDV-01 Entering Phase 3 In NMIBC, But There's No Rush To Buy Stock Today

June 19, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RLMD, AMLX, AGIO, and IOVA Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$30.54 +0.52 (+1.73%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$30.54 0.00 (0.00%)

As of 08/3/2026 07:34 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Amylyx Pharmaceuticals NASDAQ:AMLX

$20.17 -0.14 (-0.69%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$20.14 -0.03 (-0.12%)

As of 08/3/2026 07:34 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Iovance Biotherapeutics NASDAQ:IOVA

$4.32 +0.25 (+6.14%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$4.32 0.00 (-0.12%)

As of 08/3/2026 07:59 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Relmada Therapeutics NASDAQ:RLMD

$5.30 -0.01 (-0.19%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$5.28 -0.01 (-0.28%)

As of 08/3/2026 07:39 PM Eastern

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RLMD, AMLX, AGIO, and IOVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RLMD, AMLX, AGIO, and IOVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RLMD, AMLX, AGIO, and IOVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RLMD, AMLX, AGIO, and IOVA Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Amylyx Pharmaceuticals NASDAQ:AMLX

Iovance Biotherapeutics NASDAQ:IOVA

Relmada Therapeutics NASDAQ:RLMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RLMD, AMLX, AGIO, and IOVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RLMD, AMLX, AGIO, and IOVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RLMD, AMLX, AGIO, and IOVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RLMD, AMLX, AGIO, and IOVA Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Amylyx Pharmaceuticals NASDAQ:AMLX

Iovance Biotherapeutics NASDAQ:IOVA

Relmada Therapeutics NASDAQ:RLMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools